Evidence map›Paper›PMID 41952240›Full record

ArticleTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2026

Effects of the Fluid Replacement Method During Online Hemodiafiltration on the Solute Removal Performance and Biocompatibility Using the Asymmetric Cellulose Triacetate Membrane.

Kenji Sakurai, Yoshitaka Kurihara, Fumi Yamauchi, Hiromi Hosoya, Takeshi Saito

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kenji SakuraiDialysis Center, Hashimoto Clinic, Sagamihara, Kanagawa, Japan.ORCID https://orcid.org/0009-0008-4776-8945
Yoshitaka KuriharaDialysis Center, Hashimoto Clinic, Sagamihara, Kanagawa, Japan.
Fumi YamauchiDialysis Center, Hashimoto Clinic, Sagamihara, Kanagawa, Japan.
Hiromi HosoyaDialysis Center, Hashimoto Clinic, Sagamihara, Kanagawa, Japan.
Takeshi SaitoDialysis Center, Hashimoto Clinic, Sagamihara, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPre-dilution online hemodiafiltration (Pre-HDF) is predominantly used in Japan, whereas post-dilution online HDF (Post-HDF) is more common in Europe. An asymmetric cellulose triacetate (ATA) membrane may improve biocompatibility. This study compared biocompatibility and solute removal performance between Pre- and Post-HDF using the ATA membrane.

methodsEight stable maintenance hemodialysis patients underwent both Pre- (60 L/session) and Post-HDF (12 L/session) using an ATA membrane. Blood flow rate was 250 mL/min, total dialysate flow rate was 500 mL/min, and treatment time was 4 h. Biocompatibility and solute removal parameters were evaluated.

resultsWhite blood cell and platelet counts showed mild decreases; inflammatory markers remained unchanged in both modalities. CD62P expression increased more in Post-HDF. Reduction rates of urea, creatinine, and α1-microglobulin were higher in Post-HDF, while β2-microglobulin was comparable. Albumin leakage was greater in Post-HDF.

conclusionsUsing the ATA membrane, Pre- and Post-HDF showed comparable biocompatibility, while Post-HDF provided superior solute removal performance.

Indexed as

CelluloseHemodiafiltrationMembranes, ArtificialAlpha-Globulinsbeta 2-MicroglobulinBiocompatible MaterialsCreatinineDialysis SolutionsFemaleHumansJapanMaleUreaalpha-1-microglobulinAlpha-Globulinsbeta 2-MicroglobulinBiocompatible MaterialsCellulosecellulose triacetateCreatinineDialysis SolutionsMembranes, ArtificialUreaasymmetric cellulose triacetate membranebiocompatibilitypost‐dilution online HDFpre‐dilution online hemodiafiltrationsolute removal efficiency

Identifiers

PMID41952240
PMCPMC13326959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.